grepcent public filings, reorganized for comparison

LEVOTHYROXINE SODIUM — FDA application ANDA211369

Application ANDA211369 · type ANDA · FDA status: approved · original approval 2020-10-28

Listed sponsor: ANI PHARMS · ANIP company profile · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

FDA application facts

ProductFDA-listed trade nameActive ingredientDosage formRouteStrengthMarketing statusTE codeRLD
001LEVOTHYROXINE SODIUMLEVOTHYROXINE SODIUMCAPSULEORAL0.075MGDiscontinuednot listedNo
002LEVOTHYROXINE SODIUMLEVOTHYROXINE SODIUMCAPSULEORAL0.15MGDiscontinuednot listedNo
003LEVOTHYROXINE SODIUMLEVOTHYROXINE SODIUMCAPSULEORAL0.112MGDiscontinuednot listedNo
004LEVOTHYROXINE SODIUMLEVOTHYROXINE SODIUMCAPSULEORAL0.2MGDiscontinuednot listedNo
005LEVOTHYROXINE SODIUMLEVOTHYROXINE SODIUMCAPSULEORAL0.137MGDiscontinuednot listedNo
006LEVOTHYROXINE SODIUMLEVOTHYROXINE SODIUMCAPSULEORAL0.175MGDiscontinuednot listedNo

Product, form, strength, reference-drug and marketing-status fields: Drugs@FDA data files; TE and RLD fields: Orange Book data files. Retrieved 2026-08-07.

Orange Book patent and exclusivity listings

No Orange Book patent or exclusivity listings joined to this application.

Compound cross-links

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

Related pages

Sponsor company · FDA-approved application index

Peer clusters: No published peer-cluster link for this sponsor.

Sources: Drugs@FDA · Orange Book · openFDA application record. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.